Aptorum Group Limited (NASDAQ:APM) Short Interest Up 11.9% in June

Aptorum Group Limited (NASDAQ:APM) saw a large growth in short interest in June. As of June 15th, there was short interest totalling 6,600 shares, a growth of 11.9% from the May 31st total of 5,900 shares. Based on an average daily trading volume, of 44,300 shares, the short-interest ratio is presently 0.1 days. Approximately 0.3% of the shares of the stock are sold short.

Aptorum Group Trading Down 1.2 %

Shares of NASDAQ APM traded down $0.05 during mid-day trading on Tuesday, reaching $4.02. The company had a trading volume of 39,602 shares, compared to its average volume of 1,222,632. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.18 and a current ratio of 1.18. The company has a 50-day moving average price of $4.76 and a two-hundred day moving average price of $4.36. Aptorum Group has a 1-year low of $1.35 and a 1-year high of $17.49.

Hedge Funds Weigh In On Aptorum Group

An institutional investor recently bought a new position in Aptorum Group stock. Murchinson Ltd. purchased a new stake in shares of Aptorum Group Limited (NASDAQ:APM) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 14,000 shares of the company’s stock, valued at approximately $133,000. Murchinson Ltd. owned approximately 0.27% of Aptorum Group at the end of the most recent quarter. 3.80% of the stock is currently owned by institutional investors and hedge funds.

Aptorum Group Company Profile

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A.